Scientific RepoRts | 6:28309 | DOI: 10.1038/srep28309 means of UPSIT age-gender-smoking-habit-matched controls 15 . Olfactory thresholds were higher than those of controls, although statistical significance was not attained, probably because the study was not adequately powered. In another study, Marietta et al. 16 studied the olfactory acuity in a subgroup of USH1C patients. They used UPSIT test in 18 older patients, not pair matched. Although an age decline in olfaction appeared to be greater than normative data, the difference was not significant 16 . Patients with ciliopathies affecting the inner ear are frequently deaf and/or persons who exhibit balance difficulties; and patients with retinal ciliopathies often become blind 17 . Genetics, biochemistry and proteomic approaches have demonstrated that USH proteins are organized in networks in both the eye and the inner ear 18 . Consequently, a disease that have both systems affected like USH is expectable to be a sensory ciliopathy 18 . Furthermore, USH has been associated with bronchiectasis, chronic sinusitis, reduced nasal mucociliary clearance 19, 20 and altered sperm function 21 , all of which are suggestive of ciliary dyskinesia 19 .
In recent years a number of papers helped to elucidate the relationship between olfaction and its genetic underpinnings since the pioneering work of Buck and Axel, 1991 22 . Because recent evidence implicated olfaction in sensory ciliopathies 18, [23] [24] [25] [26] [27] [28] , it is expectable that olfaction is also implicated in USH, however, the few previous studies addressing functional olfactory acuity in patients with USH have showed conflicting results 12, 14, 29 .
AIM
Knowing that Usher syndrome is a ciliopathy from a histopathological and molecular standpoint, we have undertaken a prospective recruitment of patients with USH to study their functional olfactory features. This study aimed at identifying and characterizing putative differences in olfactory capacity between patients with USH and controls, as well as among the subtypes of USH.
Patients and Methods
All participants provided informed written consent. The study followed the Declaration of Helsinki 2013 on Biomedical Research Involving Human Participants and was approved by the Ethics Committee of the Faculty of Medicine, University of Coimbra, Portugal.
Sixty-five patients with USH (49.2 ± 15.1 years old; 18 females and 47 males) were prospectively recruited from the Otorhinolaryngology consultation of the Centro Hospitalar e Universitário de Coimbra, Portugal. They were pair-matched with 65 healthy controls (controls 49.2 ± 14.9 years old) for age, sex, and smoking habits, so that a total of 130 participants were studied.
All participants received a full ENT clinical examination, as well as a structured interview, a rhinologic examination including nasal endoscopy and a standardized Sniffin' Sticks test (Burghart GmbH, Wedel, Germany) culturally validated to the Portuguese population (SnSt-pt) 30 . Briefly, this test comprised three subtests, namely odor threshold (T, tested by means of a single staircase procedure), odor discrimination (D, 3-alternative forced choice) and odor identification (I, 4-alternative forced choice). Results of the 3 subtests are typically summed up and presented as a composite TDI score, as review by Hummel et al. 31 . Eligible patients had a documented neurosensory hearing loss and RP, fulfilling the clinical criteria for USH1 or USH2, as defined by the USH consortium 2 . Exclusion criteria included participants with known factors affecting olfaction, such as post-traumatic olfactory dysfunction, sinonasal disease, malignant tumor, recent radiotherapy or chemotherapy, post-upper respiratory tract infection, use medication known to interfere in olfaction 32 , and Parkinson´s and Alzheimer´s disease.
Statistical analysis of the data was performed using the Statistical Package for the Social Sciences (SPSS), version 22.0 (SPSS, Inc., Chicago, IL). The normality of continuous variables was tested with the Kolmogorov-Smirnov test. Age is displayed as mean and standard deviation. Olfactory data is presented as median and interquartile range. The Mann-Whitney U test or Student's t-test test was used whichever appropriate. In spite of the main measure being the Sniffin' Sticks TDI scores, and though it would be justifiable not to perform multiple comparisons adjustment in planned comparisons using each one of the partial measures (T, D, and I sub-scales of the Sniffin' Sticks TDI scale), the fact is that those sub-scales are not perfectly independent. As a result, the multiple comparisons problem arises, and is sorted out through the Holm's correction, which controls the Family-Wise Error Rate, and the Benjamini-Hosper correction, which controls the False Discovery Rates. Spearman´s rank correlation coefficient was calculated to verify the relationship between subgroups tested for olfaction. Multiple linear regression with previous bootstrapping was used to correlate olfaction in relation to age and Usher subtype. All tests were two-tailed and statistical significance was accepted at the p < 0.05 level. Total USH patients' vs controls. USH patients′ olfactory scores were compared to pair matched controls. Patients with USH had significantly better SnSt-composite TDI olfaction scores than healthy controls (32.8 [28.5-37.4] ) vs (30.0 [28.6-31.3] ), (p = 0.002). Both USH1 and USH2 showed better discrimination scores than controls, with large standardized effect sizes (Table 1) .
Results

Sixty
USH1 VS USH2. USH1 and USH2 are distinguishable in terms of hearing loss and vestibular function.
Patients with USH1 and USH2 were compared regarding olfaction capabilities and USH1 showed significantly higher TDI and identification scores than USH2 (Table 2 ). Effect size was 1.27 with a posteriori power of 99.87%.
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Usher syndrome olfactory age decline. A deeper look showed a significant olfactory ageing decline in patients with USH. Because olfaction is known to decline with ageing 30 and to adequately evaluate how olfactory ability is affected in USH patients, it is important to rule out ageing´s effect on olfaction. Consequently, after considering the normal age effect on olfaction based on our normative data 30 (n = 203, that compares well with original data from Hummel et al. 31 ), a multiple regression model was obtained. Patients with USH show a significantly faster age decline in olfaction. This effect is particularly relevant regarding USH1 patients: TDI = 50,010 − 0,401 × age; T = 16,549 − 0,188 × age; D = 16,248 − 0,124 × age; and I = 17,096 − 0,127 × age (Table 3) .
After correcting for normal olfactory ageing decline, patients with USH1 show a significantly faster olfactory decline with age than healthy subjects with a R 2 = 0.703 and a power of 99.99% (Table 4) . The significant olfactory decline in patients with USH1, not attributable to the olfactory ageing effect, is displayed in Fig. 1 . Normative data is presented for comparison purposes (Fig. 1) .
Considering patients with USH2, none of the models were statistically significant. Olfactory ageing effect is presented in Fig. 2 .
When comparing patients with USH1 younger or older than the mean age of the group (43 years old), the older ones show significantly lower TDI scores (11.9 ± 1.7 vs 4.9 ± 2.0, p < 0.001) ( Table 5 ). Such effect is not seen in patients with USH2.
The faster olfactory loss after adjusting for normal age related olfactory loss comparisons achieved a power of at least 91.12% in the all comparisons.
Discussion
The present study shows that patients with USH have significantly better TDI scores than healthy controls. Moreover, patients with USH1 show significantly higher TDI scores than patients with USH2, what can help to phenotypically distinguish them, having important clinical implications. A cut-off age of 43 years could be used. We observe that patients with USH1 have a faster decrease in olfactory function than what happens in healthy subjects, leading to much lower olfactory scores in older patients with USH1.
Data presented in this study indicates that olfactory tests may provide a valuable tool in characterizing and categorizing USH types. Although auditory and vestibular testing helps to distinguish typical USH patients, additional phenotypic abnormalities are necessary to aid in differentiating among atypical cases. Because of that, the current phenotype-genotype correlation is insufficient to predict the likely causative mutation, which makes . Our study tried to solve some methodology problems that highly limited the strength of conclusions from those papers. Being a rare disease, with such heterogeneous phenotypes, it is difficult to investigate a sample size with a sufficient power to confirm possible differences in olfaction among patients with Usher 12, 14, 16 . While some papers trust on the subjects' self-assessment of olfaction, it is unreliable, and testing olfactory function is necessary 33 . Moreover, some previous studies used non-standardized and not validated olfactory testing 14 . Additionally, because patients were not matched for well-known factors to affect olfaction 13, [34] [35] [36] including age, gender and smoking habits 12, 14, 37 , those studies must be interpreted with caution 38 . The better olfaction observed in young USH1 may be easily explained by the adaptive intramodal neuroplasticity and cross-modal sensory reorganization associated with blindness and by the behavioral compensations taking place in the remaining senses, including those in the tactile, auditory and olfactory domains [39] [40] [41] [42] . Recent studies on olfaction in blind persons have shown that early blindness may affect olfactory processing 39, 41, [43] [44] [45] . Not Table 4 . Decreased olfactory function related to USH1 after adjusting for age related olfactory loss. TDI: composite score of T, D and I olfactory tests. T: threshold test; D: discrimination test; I: Identification test.; CI -confidence interval. Highlighted differences should be retained as statistically significant differences. all studies have found superior olfactory capabilities in the different olfaction areas [46] [47] [48] , but discrepancies are not surprising because most studies enrolled few patients, lacked matched-pair controls and did not use standardized and cultural validated olfactory testing procedures 46, 47, 49, 50 . Patients with USH2 may have shown less significant differences because when a person is afflicted by combined visual and hearing impairment, it becomes more difficult for other sensory systems to compensate 39 . The higher scores observed in younger patients with USH, in particular in USH1, may be a compensatory olfactory effect of deaf-blindness. There is growing evidence that congenitally blind individuals outperform age-and gender matched, normally sighted persons in tactile, auditory and possibly also olfactory tasks 39, 41, 44 , but such effect is not seen in late-blindness patients 41, 45, 51 . Thus, our results are not surprising in view of the fact that both hearing and visual loss occur earlier and in a more severe manner in patients with USH1 44 . The number of cases used to perform each regression was different due to the sampling of such a rare disease, where patients with USH1 were 22 and USH2 43. In spite of the different number of cases used in both regressions, statistical power was similar thus both regressions are valid and comparable in terms of conclusions achieved. The regression models showed a power superior to 91% in all comparisons performed. When the observed effect sizes are large (between 1.27 and 4.24), a nearly null type II error exists and the p-value achieved (p < 0.001) represent a true positive value between groups. The difference between patients with USH1 and USH2 concerning TDI scores represent an effect size of 1.27 which means that the achieved a posteriori power with a sample of 22 and 43 patients is 99.87%. Therefore, we must conclude there is no bias related to the different number of patients in each group and consequently, the observed dispersion is related to the olfactory features of patients with USH. Data linking USH to a ciliopathy is grounded on histopathological and molecular studies 24, 27 . Most of the USH proteins have been localized at or around ciliary photoreceptor structures in the retina (as well as other ciliated tissues, such as olfactory epithelium) 14, 21, 52, 53 . On the other hand, a considerable body of evidence indicates that olfactory dysfunction might well be associated with ciliary disorders 18, 25, 27, 53, 54 . Proteins related to the USH have a periciliary localization and play a role in ciliogenesis and ciliary maintenance of olfactory cilia 55 . Furthermore, given the evidence linking ciliary abnormalities to USH-related pathology in the retina 18, 56 , inner ear 18,57 , nasal 27, 52, 58 and tracheal mucosa 19, 59, 60 , and sperm 21 , the consequences of a genetic olfactory cilia impairment 21, 24, 52, 56 may well explain the faster decrease in olfaction seen in this study´s patients with USH1.
Although it is the biggest study on olfaction in patients with USH to our knowledge, the results must be regarded with caution until larger series confirm it. Consequently, and because of the rarity of USH, multicenter studies are needed to investigate olfactory function in these rare cases. Moreover, a possible supra-threshold effect may have not been studied due to the possible ceiling effect of Sniffin' Sticks, something that was not explored 41 . Olfactory dysfunction should be considered in the spectrum of clinical manifestations associated with Usher syndrome. Patients with USH present better olfactory scores than controls, especially younger USH1. The olfaction difference between USH1 and USH2, as well as the major decline in olfactory ability seen in USH1, but not in USH2, may contribute to distinguish USH types and represent an attractive tool for pre diagnostic screening due to the low cost and non-invasive nature of the procedure.
